Have a feature idea you'd love to see implemented?
Let us know!
LGND Ligand Pharmaceuticals Inc
Price (delayed)
$119.19
Market cap
$2.25B
P/E Ratio
45.15
Dividend/share
N/A
EPS
$2.64
Enterprise value
$2.2B
Ligand Pharmaceuticals is a biopharmaceutical company located in San Diego, California. Founded in 1987 as Progenx Inc., the company went public in 1992.
Highlights
Ligand Pharmaceuticals's EPS has surged by 175% YoY and by 8% QoQ
Ligand Pharmaceuticals's net income has soared by 175% YoY and by 7% from the previous quarter
The debt has grown by 16% YoY but it has contracted by 3% from the previous quarter
LGND's P/E is 65% above its last 4 quarters average of 27.4
Ligand Pharmaceuticals's quick ratio has decreased by 30% QoQ and by 26% YoY
Key stats
What are the main financial stats of LGND
Market
Valuations
Earnings
Shares outstanding
18.9M
Market cap
$2.25B
Enterprise value
$2.2B
Price to earnings (P/E)
45.15
Price to book (P/B)
2.59
Price to sales (P/S)
14.4
EV/EBIT
35.94
EV/EBITDA
22.45
EV/Sales
14.41
Revenue
$152.42M
EBIT
$61.1M
EBITDA
$97.81M
Free cash flow
$24.86M
Per share
Balance sheet
Liquidity
EPS
$2.64
Free cash flow per share
$1.35
Book value per share
$46.04
Revenue per share
$8.28
TBVPS
$31.2
Total assets
$954.87M
Total liabilities
$113.69M
Debt
$7.36M
Equity
$841.18M
Working capital
$284.62M
Debt to equity
0.01
Current ratio
12.49
Quick ratio
10.7
Net debt/EBITDA
-0.58
Margins
Efficiency
Dividend
EBITDA margin
64.2%
Gross margin
93.5%
Net margin
29.7%
Operating margin
-10.7%
Return on assets
5.1%
Return on equity
5.8%
Return on invested capital
14%
Return on capital employed
6.6%
Return on sales
40.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LGND stock price
How has the Ligand Pharmaceuticals stock price performed over time
Intraday
2.27%
1 week
6.7%
1 month
11.92%
1 year
100.29%
YTD
66.89%
QTD
19.08%
Financial performance
How have Ligand Pharmaceuticals's revenue and profit performed over time
Revenue
$152.42M
Gross profit
$142.54M
Operating income
-$16.33M
Net income
$45.24M
Gross margin
93.5%
Net margin
29.7%
The net margin has soared by 178% YoY but it has contracted by 6% from the previous quarter
Ligand Pharmaceuticals's net income has soared by 175% YoY and by 7% from the previous quarter
Ligand Pharmaceuticals's gross margin has increased by 17% YoY
The gross profit has grown by 16% since the previous quarter and by 16% year-on-year
Growth
What is Ligand Pharmaceuticals's growth rate over time
Valuation
What is Ligand Pharmaceuticals stock price valuation
P/E
45.15
P/B
2.59
P/S
14.4
EV/EBIT
35.94
EV/EBITDA
22.45
EV/Sales
14.41
Ligand Pharmaceuticals's EPS has surged by 175% YoY and by 8% QoQ
LGND's P/E is 65% above its last 4 quarters average of 27.4
LGND's P/B is 36% higher than its last 4 quarters average of 1.9 and 18% higher than its 5-year quarterly average of 2.2
The equity has grown by 26% year-on-year and by 9% since the previous quarter
The price to sales (P/S) is 45% higher than the 5-year quarterly average of 9.9 and 31% higher than the last 4 quarters average of 11.0
The revenue has grown by 14% since the previous quarter
Efficiency
How efficient is Ligand Pharmaceuticals business performance
The ROA has soared by 143% YoY
The company's return on equity has surged by 123% YoY
Ligand Pharmaceuticals's ROIC has decreased by 43% YoY
Ligand Pharmaceuticals's return on sales has decreased by 8% YoY
Dividends
What is LGND's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LGND.
Financial health
How did Ligand Pharmaceuticals financials performed over time
Ligand Pharmaceuticals's quick ratio has decreased by 30% QoQ and by 26% YoY
LGND's current ratio is down by 26% since the previous quarter and by 23% year-on-year
The debt is 99% less than the equity
The equity has grown by 26% year-on-year and by 9% since the previous quarter
The debt has grown by 16% YoY but it has contracted by 3% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.